,Canonical_Smiles,drug_name,drug_type,Label
0,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
1,CC(=O)Oc1ccccc1C(=O)O,Acetylsalicylic Acid,Sulfotransferase-Substrate,positive
2,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C=O)C[C@@H]21,11_oxo_delta_8_tetrahydro_cannabinol,2D6-Substrate,negative
3,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
4,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,Metoclopramide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
5,C[C@@H](NC(=Nc1ccncc1)NC#N)C(C)(C)C,Pinacidil,2D6-Substrate,negative
6,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
7,O=C1CN=C(c2ccccc2F)c2cc(Cl)ccc2N1CC(F)(F)F,2_oxo_quazepam,2C9-Substrate,negative
8,CON=CC1=CCCN(C)C1,Milameline,2D6-Substrate,negative
9,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,Cyclobenzaprine,2D6-Substrate,negative
10,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Methylprednisolone,-,negative
11,CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc(S(C)=O)cc1,Sulindac,GST-Inducer,negative
12,O=C(O)C=Cc1ccccc1,Bemiparin,Sulfotransferase-Substrate,positive
13,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,Mosapride,-,negative
14,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate,negative
15,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
16,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,Flurazepam,2E1-Inhibitor,negative
17,CC(=O)Nc1ccc(O)cc1,Paracetamol,Sulfotransferase-Substrate,positive
18,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,Cidofovir,Solute_carrier_family_22_member_6-Substrate,negative
19,OCc1cccnc1,Nicotinyl Alcohol (pyridylcarbinol),Coumarin_7_hydroxylase-Substrate,negative
20,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Chloroquine,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
21,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Retigabine,1A1-Substrate,negative
22,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,testosterone,2C19-Substrate,negative
23,COC(=O)[C@H](c1ccccc1Cl)N1CCC2SC(=O)C=C2C1,2_oxo_clopidogrel,2D6-Substrate,negative
24,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
25,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
26,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
27,O[C@@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@@H]2C=C[C@H]1C2,Biperiden,2D6-Inhibitor,negative
28,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,CP2CI-Substrate,negative
29,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,Naloxone,2C8-Substrate,negative
30,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
31,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
32,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C,Metamizole Sodium,GST-Inducer,negative
33,O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1,Fenbufen,Multidrug_resistance_protein_1-Inducer,negative
34,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,2E1-Inhibitor,negative
35,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
36,C[C@H](C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,Pirprofen,UGT-Substrate,negative
37,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,Furosemide,2E1-Substrate,negative
38,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
39,CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,Terguride,2D6-Substrate,negative
40,CC(C)NC[C@H](O)c1ccc(O)c(O)c1,Isoprenaline,19A-Inducer,negative
41,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Sorbitol,1A2-Inhibitor,negative
42,c1ccc2c(c1)Sc1ccccc1N2C[C@@H]1CN2CCC1CC2,mequitazine,2D6-Substrate,negative
43,CNC[C@H](O)c1cccc(O)c1,Phenylephrine,19A-Inducer,negative
44,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
45,Cc1ncc2c(c1O)CO[C@@H]2c1ccc(Cl)cc1,Cicletanine,UGT-Substrate,negative
46,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,vicriviroc,2C9-Substrate,negative
47,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
48,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
49,CCN(CC)CCOC(=O)c1ccc(N)cc1,Procaine,Methyltransferase-Inhibitor,negative
50,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
51,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
52,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,Nefiracetam,-,negative
53,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Dasatinib,UGT-Inhibitor,negative
54,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor,negative
55,C=CCOc1ccccc1OC[C@H](O)CNC(C)C,Oxprenolol,2D6-Inhibitor,negative
56,C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,Tiotropium Bromide,2D6-Substrate,negative
57,C1CNCCN1,Piperazine,2D6-Substrate,negative
58,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
59,C[C@@H](C(=O)O)c1ccc(C(=O)c2ccccc2)s1,Tiaprofenic Acid,GST-Inhibitor,negative
60,Cc1cc(N(C)C)ccc1CC(C)N,Amiflamine,2D6-Substrate,negative
61,COCc1c(C(C)C)nc(C(C)C)c(C=C[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,Cerivastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
62,CNCCCN1c2ccccc2CCc2ccccc21,Desipramine,2E1-Inhibitor,negative
63,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
64,NCC(=O)CCC(=O)O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate,negative
65,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,Dextromethorphan,2E1-Substrate,negative
66,CCCCN(CCCC)N=O,NN_dibutyl_nitrosoamine,2E1-Substrate,negative
67,OC(c1ccccc1)(c1ccccc1)C1CCNCC1,Azacyclonol,-,negative
68,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,androstenedione,3A4-Substrate,negative
69,Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,Tocopherol (vit E),2E1-Inhibitor,negative
70,COc1ccc(O)cc1,Mequinol,GST-Inducer,negative
71,C[C@@H](CN1c2ccccc2Sc2ccccc21)N(C)C,Promethazine,2D6-Inhibitor,negative
72,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
73,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,Proadifen,-,negative
74,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,Enoxacin,-,negative
75,CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(C(C)=O)c1,Acebutolol,2D6-Inhibitor,negative
76,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,Dipyridamole,Multidrug_resistance_associated_protein_1-Inhibitor,negative
77,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,Ambroxol,-,negative
78,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,Amsacrine,2D6-Substrate,negative
79,CCC[C@@H]1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,Azapropazone,-,negative
80,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
81,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
82,CCCCCNC(=N)NN=Cc1c[nH]c2ccc(CO)cc12,Tegaserod,2E1-Inhibitor,negative
83,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)/C=C\CO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,lilopristone,3A4-Substrate,negative
84,CCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_ethylamphetamine,2D6-Substrate,negative
85,CCNc1nc(NC(C)(C)C)nc(SC)n1,terbutryn,2C19-Substrate,negative
86,Cc1ncc([N+](=O)[O-])n1C[C@H](O)CCl,Ornidazole,P450_HFLA-Substrate,negative
87,COc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_methoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
88,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,Sulfinpyrazone,-,negative
89,CC(C)[C@]12CC(=O)[C@@H](C)[C@H]1C2,beta_thujone,3A4-Substrate,negative
90,CC(C)(Oc1ccc([C@H]2CC2(Cl)Cl)cc1)C(=O)O,Ciprofibrate,4A11-Inducer,negative
91,COc1ccc2c(c1)c(CC(=O)NCC(O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,2_hydroxy_indomethacin_phenethylamide,2D6-Substrate,negative
92,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,-,negative
93,CN(C)N=O,NN_dimethyl_nitrosoamine,2E1-Substrate,negative
94,CCN(CC)CCc1nc(-c2ccccc2)no1,Oxolamine,1B1-Inducer,negative
95,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,Anastrozole,19A-Inhibitor,negative
96,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Lisuride,2D6-Substrate,negative
97,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Fluconazole,CP2CI-Inhibitor,negative
98,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
99,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,19A-Inhibitor,negative
100,Cc1ccsc1-c1ccc([C@H](C)C(=O)O)cc1,S_MTPPA,2C9-Substrate,negative
101,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
102,COc1c2occc2cc2ccc(=O)oc12,Methoxsalen,-,negative
103,O=C(O[C@@H]1C[C@@H]2C[C@@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,Dolasetron,2D6-Substrate,negative
104,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
105,CN(C)c1ccc(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)cc1,Lilopristone,-,negative
106,CCN(CC)C(=S)SC,DDTC_Me,2E1-Substrate,negative
107,COc1cc(-c2cc3c(c(=O)o2)C[C@]2(O)[C@](C)(CC[C@@]4(O)C(C)(C)C=CC(=O)[C@@]42C)O3)cc2c1OCO2,territrem_A,2D6-Substrate,negative
108,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
109,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
110,Cc1cc(Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,Disulfamide,-,negative
111,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Ecabapide,-,negative
112,CN1C2CC[C@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,2D6-Substrate,negative
113,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,Benzatropine,2D6-Substrate,negative
114,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
115,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Adriamycin,GST-Substrate,negative
116,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
117,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
118,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,Loratadine,2D6-Inhibitor,negative
119,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
120,COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,Yohimbine,2D6-Substrate,negative
121,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Methylergometrine,-,negative
122,COC(C)(C)C,methyl_tert_butyl_ether,2E1-Substrate,negative
123,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
124,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
125,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine_R,2C8-Substrate,negative
126,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[C@@H](C(=O)N(C)C)N3)[C@H](C)[C@H]12,Meropenem,Solute_carrier_family_22_member_6-Substrate,negative
127,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
128,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,deoxycholic_acid,3A4-Substrate,negative
129,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
130,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,P450_HFLA-Substrate,negative
131,CCCC(=O)O,Hydroxybutyric Acid,Monocarboxylate_transporter_1-Substrate,negative
132,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Idebenone,1A2-Substrate,negative
133,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,Mepacrine,Methyltransferase-Inhibitor,negative
134,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
135,NCCS,Mercaptamine,GST-Inhibitor,negative
136,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,2D6-Substrate,negative
137,Cn1c(=O)c2[nH]cnc2n(C)c1=O,Aminophylline,2E1-Substrate,negative
138,Nc1ccc(C(=O)NCC(=O)O)cc1,Aminohippuric Acid,Solute_carrier_family_22_member_6-Substrate,negative
139,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,Pantoprazole,Sulfotransferase-Substrate,positive
140,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,negative
141,N=C(N)NC(=N)NCCc1ccccc1,Phenformin,2D6-Substrate,negative
142,COc1ccc2cc(C#N)c(=O)oc2c1,7_methoxy_3_cyano_coumarin,2E1-Substrate,negative
143,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
144,CC[C@H](C(N)=O)N1CCCC1=O,Levetiracetam,GST-Inducer,negative
145,CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C,Etretinate,19A-Inhibitor,negative
146,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,Ziprasidone,P450_HFLA-Substrate,negative
147,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
148,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=C[C@H](O)C[C@@H](O)CC(=O)O,Rosuvastatin,Sodiumbile_acid_cotransporter-Substrate,negative
149,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
150,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,-,negative
151,CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12,Maprotiline,2D6-Substrate,negative
152,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,Mirtazapine,2D6-Inhibitor,negative
153,CCCCCCCCCCCC(=O)O,lauric_acid,2E1-Substrate,negative
154,CNCCCN1c2ccccc2CCc2ccc(Cl)cc21,N_desmethyl_clomipramine,2D6-Substrate,negative
155,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
156,CC(C)(C=O)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_aldehyde_finasteride,3A4-Substrate,negative
157,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
158,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12,Aldosterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
159,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Ergoloid Mesylates,Solute_carrier_organic_anion_transporter_family_member_2B1-Inhibitor,negative
160,COc1ccc2[nH]c3c([N+](=O)[O-])ccc4c3c(nn4CCCN(C)C)c2c1,pyrazolo_acridine,1A2-Substrate,negative
161,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
162,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
163,CC(C)(C)C(O)C=Cc1ccc2c(c1)OCO2,Stiripentol,-,negative
164,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
165,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,Eszopiclone,2E1-Substrate,negative
166,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,Eslicarbazepine,UGT-Substrate,negative
167,Cc1ncc(CO)c(CO)c1O,Pyridoxine (vit B6),Methyltransferase-Inhibitor,negative
168,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
169,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Deferoxamine,1A1-Inhibitor,negative
170,CCO,Ethanol,4A11-Inducer,negative
171,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,Raloxifene,19A-Inhibitor,negative
172,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,Trimetrexate,-,negative
173,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
174,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,Brompheniramine,2E1-Substrate,negative
175,CCCN(CCC)CCc1cccc2c1CC(=O)N2,Ropinirole,2D6-Inhibitor,negative
176,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
177,CN[C@H](C)Cc1ccccc1,methamphetamine_R,2D6-Substrate,negative
178,CNC(=NC#N)NCCSCc1nc[nH]c1C,Cimetidine,2E1-Inhibitor,negative
179,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@]21CCC(=O)O1,Canrenone,UGT-Inhibitor,negative
180,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
181,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
182,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,Benidipine,2D6-Inhibitor,negative
183,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
184,CN(C)CCOC(c1ccccc1)c1ccccc1,Diphenhydramin,2D6-Substrate,negative
185,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
186,CC(N)Cc1ccc(O)cc1,Hydroxyamfetamine,2D6-Substrate,negative
187,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,Benoxaprofen,1A2-Inducer,negative
188,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,Ganciclovir,Neutral_amino_acid_transporter_B0-Substrate,negative
189,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,Valsartan,-,negative
190,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
191,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,negative
192,C[C@@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,suprofen_R,2C9-Substrate,negative
193,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc([N+](=O)[O-])c1,Nilvadipine,2E1-Substrate,negative
194,Cc1ccc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)nc1,Glipizide,-,negative
195,Cc1ccccc1C,xylene_ortho,2E1-Substrate,negative
196,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,fluvoxamine,2D6-Substrate,negative
197,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,Azatadine,-,negative
198,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,Calcitriol,SUL-Inducer,negative
199,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,19A-Inhibitor,negative
200,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2E1-Inhibitor,negative
201,CN1C(=O)OC(C)(C)C1=O,Trimethadione,2E1-Substrate,negative
202,O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,Atovaquone,-,negative
203,OCC(O)CO,Glycerol,2E1-Inducer,negative
204,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,-,negative
205,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
206,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,Docetaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
207,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
208,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,simvastatin_hydroxy_acid,2C8-Substrate,negative
209,Cc1ccc(O)c([C@@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,Tolterodine,2D6-Substrate,negative
210,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,Oxymetazoline,UGT-Substrate,negative
211,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,Probenecid,-,negative
212,C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@H](C(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCCCN)NC1=O,Somatostatin,2D6-Inhibitor,negative
213,CC(=O)Nc1ccccc1,Acetanilide,-,negative
214,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
215,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Pentoxifylline,GST-Inducer,negative
216,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
217,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
218,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
219,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
220,O=C1CN(N=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,Dantrolene,-,negative
221,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
222,O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1,imidacloprid,2E1-Substrate,negative
223,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,Androstanolone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate,negative
224,CC1=CC[C@H]2[C@@H](C1)C2(C)C,delta_3_carene,2D6-Substrate,negative
225,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,negative
226,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
227,C=Cc1ccccc1,styrene,2E1-Substrate,negative
228,NC(=O)c1c(Cl)c(-c2cccnc2)n2c1C(O)CCC2,RPR_127025,3A4-Substrate,negative
